CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide
With a 5-year dividend growth rate of 15.23%, Eli Lilly and Company (NYSE:LLY) is among the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years. CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide In a CNBC report published on May 21, Eli Lilly and Company (NYSE:LLY) said its experimental obesity…